DOH names 3 breast cancer centres: what Dubai patients should check before referral

For a patient in Dubai, the Department of Health – Abu Dhabi designation of three Oncology Centres of Excellence for Breast Cancer means one practical change: Abu Dhabi now has a regulator-named shortlist for complex breast cancer care, but access still depends on referral, insurance approval and clinical need.

The highest-value readers for this story are patients and family decision-makers, medical directors, and insurers. The patient question is immediate: where should a newly diagnosed person go after an abnormal mammogram or biopsy? The medical director question is whether a Dubai case should stay within a Dubai Health Authority (DHA) licensed pathway or move to a Department of Health – Abu Dhabi (DOH) centre for a second opinion, surgery, systemic therapy or radiotherapy.

What changed for Dubai patients

DOH said on 21 September 2026 that Burjeel Cancer Institute at Burjeel Medical City, Cleveland Clinic Abu Dhabi and SEHA Tawam Hospital had been designated as Oncology Centres of Excellence for Breast Cancer. The announcement does not replace Dubai oncology providers. It gives Dubai patients a named Abu Dhabi benchmark when they ask for a second opinion or a referral for a complex case.

DOH’s own Centre of Excellence guidance says a patient is referred to a CoE by a clinician when CoE treatment is necessary. It also says non-UAE residents can be referred, with payment through self-pay or medical insurance coverage. That matters for Dubai residents because the referral route is usually clinical first, then insurer approval, then appointment scheduling.

• Screening trigger: DHA’s 2024 periodic screening guideline advises females aged 40 years and over to have a mammogram every 2 years.
• Higher-risk patients: DHA says screening may start earlier where there is family history or a known inherited genetic mutation, based on clinician advice.
• Abu Dhabi option: the DOH shortlist has 3 named breast cancer CoEs, all regulated by DOH.
• Dubai regulator: Dubai facilities and professionals remain licensed by DHA; northern emirates providers fall under the Ministry of Health and Prevention (MOHAP).

Insurance is the first operational barrier

A Dubai patient should not assume that a DOH designation creates automatic coverage in Abu Dhabi. Before booking outside Dubai, ask the insurer for written confirmation on network status, referral requirements, pre-authorisation, co-payment, annual limit and whether pathology, genetic testing, chemotherapy, immunotherapy, radiotherapy and reconstruction are handled under separate approvals.

For Dubai basic cover, DHA’s Basma Programme is relevant because DHA describes it as supporting cancer and hepatitis patients through screening, early detection and treatment coverage at DHA-accredited specialised medical centres. DHA lists breast, colorectal and cervical cancer among the covered cancer types. Patients should confirm eligibility through their insurer and treating hospital, because programme access is tied to policy status and clinical criteria.

Self-pay pricing is harder to standardise. UAE regulators do not publish a single national tariff for private breast cancer treatment. A useful cash quote should separate at least five items: consultation, imaging, biopsy and pathology, surgery, and systemic treatment. If a hospital gives one figure, ask whether it includes HER2, ER and PR testing, genomic tests, port insertion, radiotherapy planning, complications, day-care medicines and follow-up visits.

How to use the Abu Dhabi shortlist

The shortlist is most useful after a confirmed diagnosis or a high-suspicion result, rather than as the first step for routine screening. In Dubai, the first move for an asymptomatic woman aged 40 or above is a DHA-licensed screening provider or the provider named by her insurer. After an abnormal result, the patient should collect the mammogram images, ultrasound report, biopsy slides or blocks, pathology report and insurance card before asking for a breast multidisciplinary team review.

Abu Dhabi may be relevant where the case needs coordinated surgery, medical oncology, radiation oncology, genetics, reconstruction or trial assessment. It may also help when a patient wants a second opinion before mastectomy, neoadjuvant chemotherapy or targeted therapy. The limiting factor is time. For a suspicious lump, waiting for a distant appointment can be worse than starting the diagnostic pathway locally and transferring records once staging is clear.

Patients in Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain should check MOHAP-licensed options first, then ask whether referral to Dubai or Abu Dhabi is covered by their plan. For Dubai patients, the practical sequence is simple: screen on time, secure diagnosis, get written insurer approval, then compare DHA-licensed oncology providers with the DOH-designated Abu Dhabi centres.

To find licensed oncology providers before making calls, use the UAE Open Healthcare Directory, then verify the doctor, facility licence and insurance acceptance with DHA, DOH or MOHAP records before booking.